DMPK Consultancy

Physicochemical Properties of Drugs

It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.

In Silico and PBPK Modelling

Sygnature In Silico Modelling uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data integration within the context of a virtual animal or human model.

In Vitro ADME Pharmacology

The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME Pharmacology) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development. 

In Vivo Pharmacokinetics (PK)

At Sygnature Discovery we offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS

Bioanalysis

Sygnature’s state-of-the-art non-GLP bioanalysis service brings together the latest instrumentation and technology, which, combined with the wealth of experience across the team, is used to provide quantitative measures of metabolites for the purpose of pharmacokinetics, toxicokinetics, bioequivalence and exposure-response studies.

Metabolite Drug Identification (Met-ID)

Sygnature’s DMPK and biotransformational capabilities are supplemented by extensive expertise in complementary analytical techniques, including high-resolution mass spectrometry, nuclear magnetic resonance, chemically intelligent software algorithms and mass spectrometry imaging.